BiotechTube
Anumana

Anumana

Cambridge, United States· Est.
anumana.ai
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

Anumana is a private, commercial-stage AI diagnostics company that has successfully secured FDA clearance for its first algorithm detecting pulmonary hypertension, alongside a previously cleared algorithm for low ejection fraction. Its core strength lies in a proprietary AI platform trained on a massive, longitudinal dataset of over 22 million patient records, allowing it to extract novel clinical insights from standard ECGs. The company emphasizes seamless EHR integration and workflow compatibility to drive clinical adoption. With a growing pipeline of cardiac-focused algorithms and strong academic validation, Anumana is positioned as a leader in AI-enhanced cardiovascular diagnostics.

Cardiovascular

Technology Platform

ECG-AI™ platform trained on >22 million patient records and ~2.9 million ECG-echo pairs. Analyzes standard 12-lead ECG data to detect subtle signals of disease. Deploys on-premise within hospital IT/ECG systems for secure, integrated processing.

Funding History

2
Total raised:$60M
Series B$40M
Series A$20M

Opportunities

The massive installed base of ECG devices and high volume of tests performed globally provides a ready-made channel for deploying software upgrades that enhance diagnostic yield without new capital equipment.
Early detection of chronic cardiovascular conditions like heart failure and pulmonary hypertension can significantly reduce long-term healthcare costs, creating a powerful value-based care argument for payers and health systems.
The platform's design for on-premise, integrated deployment directly addresses major healthcare IT concerns around data privacy and workflow disruption, potentially accelerating adoption compared to cloud-only solutions.

Risk Factors

Sustainable commercial success depends on overcoming clinical inertia and securing permanent, adequate reimbursement from insurance payers beyond temporary CPT III codes.
The competitive landscape in AI-cardiology is intensifying, with risks from both well-funded startups and large, established medtech companies integrating AI into their own platforms.
Each new algorithm requires extensive, costly clinical validation and regulatory clearance, and real-world performance may vary across different patient demographics and clinical settings, posing validation and liability risks.

Competitive Landscape

Anumana competes in the growing AI-enhanced ECG diagnostics space. Direct competitors include other startups like Eko Health (which has FDA clearances for detecting low ejection fraction and murmurs) and Ultromics (focused on echocardiography AI). Large medical technology companies such as GE HealthCare, Philips, and Siemens Healthineers are also developing and acquiring AI capabilities for cardiovascular diagnostics, potentially bundling them with hardware. Anumana's key differentiators are the unparalleled scale of its training data from the Mayo Clinic/nference partnership, its focus on seamless, secure EHR integration, and its expanding portfolio of algorithms targeting high-value, difficult-to-diagnose conditions.

More companies in AI / Machine Learning →More companies in United States →